Skip to main content
main-content

Neuer Inhalt Free registration

Gain full access to the latest clinical content available from Springer Nature

Editors' pick

12-14-2017 | Guidelines | Editorial | Article

What is new in the 2018 American Diabetes Association Standards of Medical Care in Diabetes?

Jay Shubrook, Chair of the American Diabetes Association’s Primary Care Advisory Group, outlines what's new in 2018's ADA Standards of Care update. 

12-11-2017 | Glycemic control | News

Individualized type 2 diabetes management is cost-effective and enhances QoL

Health policies that focus on the individualized management of glycemic control in adults with type 2 diabetes may reduce costs and increase quality of life compared with a uniform approach of intensive control for all individuals, according to a US study.

12-13-2017 | Diagnosis | Case report | Article

Atypical diabetes: Case 3

How would you diagnose and treat the third patient in our case series on atypical forms of diabetes? Editorial board member Jay Shubrook challenges you.

Latest from across the site

12-15-2017 | Insulin degludec/Liraglutide | News

Real-world data confirm benefits of IDegLira

IDegLira, which combines the basal insulin degludec with the glucagon-like peptide-1 receptor agonist liraglutide, improves glycemic control within 6 months of initiation irrespective of previous therapy, real-world study data show.

Source:

Diabetes Obes Metab 2017; Advance online publication

12-14-2017 | Guidelines | Editorial | Article

What is new in the 2018 American Diabetes Association Standards of Medical Care in Diabetes?

Jay Shubrook, Chair of the American Diabetes Association’s Primary Care Advisory Group, outlines what's new in 2018's ADA Standards of Care update. 

Author:
Jay Shubrook DO

12-14-2017 | Empagliflozin | News

News in brief

Plasma volume reduction may explain much of empagliflozin cardioprotective effect

A mediation analysis indicates that empagliflozin may provide cardioprotection largely through its ability to reduce plasma volume, with traditional cardiovascular risk markers playing little or no role.

12-14-2017 | Hypoglycemia | News

Automatic insulin pump suspension reduces hypoglycemia in adolescents with diabetes

Children and adolescents with type 1 diabetes using a predictive low-glucose management system have less hypoglycemia and fewer hypoglycemic events than those managed using sensor-augmented pump therapy alone, according to a 6-month trial.

Source:

Diabetes Care 2017; Advance online publication

12-13-2017 | Cardiovascular outcomes | News

Prognostic value of UACR depends on availability of cardiac biomarkers

An increased urinary albumin to creatinine ratio is significantly and independently associated with an increased risk for cardiovascular outcomes in patients with type 2 diabetes, an analysis of SAVOR-TIMI 53 data shows.

Source:

JAMA Cardiol 2017; Advance online publication

12-13-2017 | Diagnosis | Case report | Article

Atypical diabetes: Case 3

How would you diagnose and treat the third patient in our case series on atypical forms of diabetes? Editorial board member Jay Shubrook challenges you.

Author:
Jay Shubrook DO

Meet our Editorial Board

Lori BerardSanjay KalraJay ShubrookProfessor John WildingCarol Wysham

New Content Item Meet our Advisory Board

image credits